Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Eli Lilly's Orforglipron shows promising Phase III ... which assessed the therapeutic effects of Orforglipron in adults with type II diabetes and inadequate blood sugar control.

LLY is bullish in weekly sequence from all time low. It favors rally in (V) after double correction ended at $677.09 low in ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Thank you for joining us for Eli Lilly & Company's Q1 2025 earnings call ... There are actually 2 Phase II trials. The first one that was conducted actually before we acquired the asset was ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

In an encouraging development, last week, Lilly announced positive data from a phase III study evaluating its next-generation once-daily oral GLP-1 agonist, orforglipron, in patients with type II ...